Efficacy of rituximab in refractory neuromyelitis optica
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Efficacy of rituximab in refractory neuromyelitis optica |
| Type de publication | Journal Article |
| Year of Publication | 2016 |
| Auteurs | Collongues N., Brassat D., Maillart E., Labauge P., Ouallet J.C, Carra-Dalliere C., Moreau T., Bourre B., Papeix C., Brochet B., Audoin B., Vukusic S., De Seze J., Marignier R., CFSEP OFSEP |
| Journal | MULTIPLE SCLEROSIS JOURNAL |
| Volume | 22 |
| Pagination | 955-959 |
| Date Published | JUN |
| Type of Article | Article |
| ISSN | 1352-4585 |
| Mots-clés | body mass index, Disability, neuromyelitis optica, refractory, Rituximab |
| Résumé | Background: Despite a growing use of rituximab (RTX) in neuromyelitis optica (NMO), data are lacking in patients with refractory NMO (RNMO), defined as cases with at least one relapse during immunosuppressive therapy. Objective: The purpose of this study was to assess RTX as a maintenance therapy in RNMO. Methods: Out of a total of 305 NMO cases from a population-based cohort, 21 RNMO patients received RTX during a mean follow-up period of 31 months. Results: After RTX, 11 patients (52.3%) were relapse free, meaning that 47.7% were refractory to RTX. The mean annualized relapse rate decreased from 1.3 to 0.4 (p<0.001) and median EDSS from 5 to 3 (p=0.02). Body mass index (BMI) was predictive of EDSS worsening. Conclusions: RTX is an effective and well-tolerated treatment in RNMO. BMI could be a predictive factor for efficacy. |
| DOI | 10.1177/1352458515602337 |